000 01400nam  2200301za 4500
0019.847520
003CaOODSP
00520221107153448
007cr |||||||||||
008171121s2018    onca    o    f000 0 eng d
020 |a9780660239385|z9780660239392
040 |aCaOODSP|beng
043 |an-cn---
0861 |aNR16-173/2017E-PDF
1102 |aNational Research Council Canada.
24510|aAMVAD adjuvant for mucosal vaccines (L-11561) |h[electronic resource].
260 |a[Ottawa] : |bNational Research Council Canada, |c[2018]
300 |a[2] p. : |bill.
500 |aIssued also in French under title: Adjuvant AMVAD pour vaccins muqueux (L-11561).
500 |aCaption title.
500 |a"January 2017."
520 |a“The NRC has developed a novel archaeal polar lipid mucosal vaccine adjuvant and delivery (AMVAD) platform capable of generating mucosal and systemic immune responses against a wide range of pathogens that infect mucosal surfaces or use them to gain entry to the body”--Highlights, p. [1].
530 |aIssued also in print format.
693 4|aImmunological adjuvants
693 4|aLiposomes
77508|tAdjuvant AMVAD pour vaccins muqueux (L-11561) |w(CaOODSP)9.847522
7760#|tAMVAD adjuvant for mucosal vaccines |w(CaOODSP)9.847521
85640|qPDF|s166 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-173-2017-eng.pdf